Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 21 June 2017, the Cambodia Oxford Medical Research Unit (COMRU) and Angkor Hospital for Children (AHC) hosted the kick-off meeting for the multi-country Real-time Tracking of Neglected Bacterial Infectious Diseases Resistance Patterns Asia (TuNDRA) study.

Group photo in Siem Reap

Investigators discussed final details of this 5-year study, which will enrol children aged 0-59 months in Cambodia, Bangladesh and Viet Nam who have been hospitalised with suspected invasive bacterial infection. TuNDRA will identify the bacteria causing severe infections, the antibiotic resistance in those organisms and determine the proportion of children with suspected bacterial infection who are potentially unnecessarily treated with antibiotics.

“The study is important given current global concerns about antimicrobial resistance (AMR),” said study collaborator and COMRU Director Dr Paul Turner. “Very few sites in low- and middle-income Asian countries are doing systematic collection of blood cultures in children with suspected invasive bacterial infection.”

TuNDRA will recruit in Bangladesh (Dhaka, Child Health Research Foundation), Cambodia (Angkor Hospital for Children, COMRU), and Vietnam (Ho Chi Minh City, OUCRU). The study is funded by the German Federal Ministry of Health and co-ordinated by the Robert Koch Institute (RKI), Germany and the International Vaccine Institute (IVI), South Korea.

TuNDRA investigators will collect samples to determine the bacteria responsible for these infections and their antimicrobial resistance profiles. Bacterial isolates will be sent to Prof Stephen Baker at OUCRU for whole genome sequencing at regular intervals throughout the study. In addition to culture, blood will tested for detection of dengue infection and swabs will be collected for PCR detection of key respiratory viruses.

“Incorporating near real-time whole genome sequencing of key bacterial species will allow us to generate data on the prevalence and genetic mechanisms associated with anti-microbial resistance across the region,” noted Dr. Turner.

The kick-off meeting was followed by a one-day training on study procedures and data entry. Recruitment is expected to begin in early July.

Similar stories

AMR and scrub typhus among Chiangrai Unit's research priorities

Which infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.

Researchers call for access to Ivermectin for young children

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

The COVID-19 vaccine: do we know enough to end the pandemic?

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.